Drug intelligence / Profile preview

Fleboside

Development stage: Unknown
Lead developer: Acarpia Farmaceutici
Modality: Small Molecules
Administration: Oral, Intramuscular

Overview

Fleboside is a fixed-dose combination pharmaceutical product containing troxerutin and carbazochrome, developed and marketed by Acarpia Farmaceutici. Troxerutin is a bioflavonoid derivative of rutin that functions as a venotonic and capillary-protective agent, reducing capillary permeability and improving venous tone. Carbazochrome is a hemostatic agent that enhances capillary resistance and reduces bleeding time. The combination is indicated for the treatment of symptoms associated with chronic venous insufficiency and states of capillary fragility. It is available in Italy in both oral tablet and intramuscular injectable formulations.

Brand names: Fleboside
Other names: troxerutin + carbazochrome

Targets

ADRA1A (α1A)

Beyond the preview

Go deeper on Fleboside.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fleboside.

Explore the full profile